Drugs / BAMOCAFTOR
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03029455 | Nov 2016 → Aug 2017 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03224351 | Aug 2017 → Feb 2018 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT03633526 | Aug 2018 → Jan 2019 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Terminated | No outcome recorded |
| Phase 3 | NCT03447262 | Jul 2018 → Sep 2020 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Terminated | No outcome recorded |
| Phase 3 | NCT03460990 | May → Sep 2018 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT03447249 | Mar 2018 → Feb 2019 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-11-27 | Vertex Pharmaceuticals Incorporated | Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis vrtx.com ↗ |
| 2018-09-06 | Vertex Pharmaceuticals Incorporated | Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis vrtx.com ↗ |
| 2018-03-01 | Vertex Pharmaceuticals Incorporated | Vertex Initiates Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation vrtx.com ↗ |
| 2018-02-21 | Vertex Pharmaceuticals Incorporated | Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis vrtx.com ↗ |
| 2018-02-01 | Vertex Pharmaceuticals Incorporated | Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis vrtx.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAMOCAFTOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297849 ↗ |
| Known as | BAMOCAFTOR POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297849 ↗ |
| Known as | VX-659 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03447249 ↗ |
| Known as | VX-659 POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297849 ↗ |
| Known as | VX-659 potassium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297849 ↗ |
| Action | Restore | “was developed to restore the function of Phe508del CFTR protein” PMID 30334693 ↗ Oct 2018 |
| Modality | Small molecule | — CHEMBL4297849 ↗ |
| Route | Oral | “A range of oral VX-659-tezacaftor-ivacaftor doses in triple combination were then evaluated” PMID 30334693 ↗ Oct 2018 |
| Target | CFTR | “was developed to restore the function of Phe508del CFTR protein” PMID 30334693 ↗ Oct 2018 |